PART I Company Overview We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to ...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001785530-26-000006 | EDGAR | 117K words |
| 2025-03-11 | 2024-12-31 | 0001785530-25-000008 | EDGAR | — |
| 2024-03-07 | 2023-12-31 | 0001785530-24-000012 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001785530-23-000009 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0001785530-22-000014 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-31 | 2026-06-30 | 0001785530-26-000019 | EDGAR | — |
| 2025-11-04 | 2025-09-30 | 0001785530-25-000031 | EDGAR | 71K words |
| 2025-08-14 | 2025-06-30 | 0001785530-25-000021 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001785530-25-000014 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001785530-24-000034 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001785530-24-000028 | EDGAR | — |
| 2024-05-03 | 2024-03-31 | 0001785530-24-000020 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001785530-23-000033 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001785530-23-000025 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001785530-23-000017 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001785530-22-000038 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001785530-22-000031 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-31 | 0001785530-26-000018 | EDGAR | — |
| 2026-03-27 | 0001785530-26-000005 | EDGAR | 2K words |
| 2026-02-24 | 0001193125-26-067569 | EDGAR | — |
| 2026-02-13 | 0001193125-26-051455 | EDGAR | — |
| 2026-02-06 | 0001193125-26-041305 | EDGAR | — |
| 2025-12-18 | 0001193125-25-323787 | EDGAR | — |
| 2025-11-04 | 0001785530-25-000030 | EDGAR | — |
| 2025-10-06 | 0001193125-25-231953 | EDGAR | — |
| 2025-08-14 | 0001785530-25-000020 | EDGAR | — |
| 2025-06-13 | 0001193125-25-140727 | EDGAR | — |
80 total filings indexed. 53 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001785530 |
| Ticker | HOWL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.werewolftx.com |
| Listed | 2021-04-30 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/HOWL (~200 tokens, structured JSON with cryptographic provenance)